По материалам клинических рекомендаций по ведению больных с дифференцированными нейроэндокринными опухолями илеоеюнальной локализации

Полный текст рекомендаций: B. Eriksson, G. Kloppel, E. Krennin, H. Ahlman, U. Phckinger, B. Wiedenmann, R. Arnold, C. Auernhammer, M. Когжг, G. Rindi, S. Wildi et al. Neuroendocrinology 2008, 87, р. 8-19

1. B. Eriksson, G. Kloppel, E. Krennin, H. Ahlman, U. Phckinger, B. Wiedenmann, R. Arnold, C. Auernhammer, M. Когжг, G. Rindi, S. Wildi et al. Neuroendocrinology 2008, 87, р. 8-19

2. Modlin IM, Lye KD, Kidd M: A five-decade analysis of 13,715 carcinoid tumors. Cancer 2003; 97: 934-959.

3. Kulke MH, Mayer RJ: Carcinoid tumors. N Engl J Med 1999; 340: 858-868.

4. Burke AP, Thomas RM, Elsayed AM, Sobin LH: Carcinoids of the jejunum and ileum: an immunohistochemical and clinicopathologic study of 167 cases. Cancer 1997; 79: 10861093.

5. Peck JJ, Shields AB, Boyden AM, Dworkin LA, Nadal JW: Carcinoid tumors ofthe ileum. Am J Surg 1983; 146: 124-132.

6. Modlin IM, Sandor A: An analysis of 8,305 cases of carcinoid tumors. Cancer 1997; 79: 813-829.

7. Loftus JP, van Heerden JA: Surgical management of gastrointestinal carcinoid tumors. Adv Surg 1995; 28: 317-336.

8. Godwin JD 2nd: Carcinoid tumors. An analysis of 2,837 cases. Cancer 1975; 36: 560569.

9. Solcia E KG, Sobin LH, in collaboration with 9 pathologists from 4 countries: Histological Typing of Endocrine Tumors, ed 2. WHO International Histological Classification of Tumors. Berlin, Springer, 2000.

10. Berge T, Linell F: Carcinoid tumours. Frequency in a defined population during a 12year period. Acta Pathol Microbiol Scand [A] 1976; 84: 322-330.

11. Strodel WE, Talpos G, Eckhauser F, Thompson N: Surgical therapy for small-bowel carcinoid tumors. Arch Surg 1983; 118: 391-397.

12. Marshall JB, Bodnarchuk G: Carcinoid tumors of the gut. Our experience over three decades and review of the literature. J Clin Gastroenterol 1993;16:123-129.

13. McDermott EW, Guduric B, Brennan MF: Prognostic variables in patients with gastrointestinal carcinoid tumours. Br J Surg 1994; 81: 1007-1009.

14. Arnold R, Rinke A, Klose KJ , et al: Octreotide versus octreotide plus interferon_ in endocrine gastroenteropancreatic tumors: a randomized trial. Clin Gastroenterol Hepatol 2005; 3: 761-771.

15. Oberg K: Chemotherapy and biotherapy in neuroendocrine tumors. Curr Opin Oncol 1993; 5: 110-120.

16. Moertel CG: Karnofsky memorial lecture. An odyssey in the land of small tumors. J Clin Oncol 1987; 5: 1502-1522.

17. Creutzfeldt W: Carcinoid tumors: development of our knowledge. World J Surg 1996; 20: 126-131.

18. Oberg K: The use of chemotherapy in the management of neuroendocrine tumors. Endocrinol Metab Clin North Am 1993; 22: 941-952.

19. Ahlman H, Westberg G, Wangberg B , et al: Treatment of liver metastases of carcinoid tumors. World J Surg 1996; 20: 196-202.

20. Zuetenhorst JM, Bonfrer JM, Korse CM, Bakker R, van Tinteren H, Taal BG: Carcinoid heart disease: the role of urinary 5-hydroxyindoleacetic acid excretion and plasma levels of atrial natriuretic peptide, transforming growth factor_ and fibroblast growth factor. Cancer 2003; 97: 1609-1615.

21. Norheim I, Oberg K, Theodorsson-Norheim E , et al: Malignant carcinoid tumors. An analysis of 103 patients with regard to tumor localization, hormone production, and survival. Ann Surg 1987; 206: 115-125.

22. Makridis C, Rastad J, Oberg K, Akerstrom G: Progression of metastases and symptom improvement from laparotomy in midgut carcinoid tumors. World J Surg 1996; 20: 900907.

23. Westberg G, Wangberg B, Ahlman H, Bergh CH, Beckman-Suurkula M, Caidahl K: Prediction of prognosis by echocardiography in patients with midgut carcinoid syndrome. Br J Surg 2001; 88: 865-872.

24. Krenning EP, Kwekkeboom DJ, Bakker WH , et al: Somatostatin receptor scintigraphy with [ 111 In-DTPAD -Phe 1 ]and [ 123 I-Tyr 3 ]-octreotide: the Rotterdam experience with more than 1,000 patients. Eur J Nucl Med 1993; 20: 716-731.

25. Hofmann M, Maecke H, Borner R , et al: Biokinetics and imaging with the somatostatin receptor PET radioligand 68 Ga-DOTATOC: preliminary data. Eur J Nucl Med 2001; 28: 1751-1757.

26. Ricke J, Klose KJ, Mignon M, Oberg K, Wiedenmann B: Standardisation of imaging in neuroendocrine tumours: results of a European delphi process. Eur J Radiol 2001; 37: 8-17.

27. Kaltsas G, Rockall A, Papadogias D, Reznek R, Grossman AB: Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours. Eur J Endocrinol 2004; 151: 15-27.

28. Bader TR, Semelka RC, Chiu VC, Armao DM, Woosley JT: MRI of carcinoid tumors: spectrum of appearances in the gastrointestinal tract and liver. J Magn Reson Imaging 2001; 14: 261-269.

29. Orlefors H, Sundin A, Garske U , et al: Wholebody 11 C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. J Clin Endocrinol Metab 2005; 90: 3392-3400.

30. Koopmans KP, de Vries EG, Kema IP , et al: Staging of carcinoid tumours with 18 F-DOPA PET: a prospective, diagnostic accuracy study. Lancet Oncol 2006; 7: 728-734.

31. Van Tuyl SA, van Noorden JT, Timmer R, Stolk MF, Kuipers EJ, Taal BG: Detection of small-bowel neuroendocrine tumors by video capsule endoscopy. Gastrointest Endosc 2006; 64: 66-72.

32. Swain P: Wireless capsule endoscopy. Gut 2003; 52(suppl 4):48-50.

33. Oberg K, Stridsberg M: Chromogranins as diagnostic and prognostic markers in neuroendocrine tumours. Adv Exp Med Biol 2000; 482: 329-337.

34. Ardill JE, Erikkson B: The importance of the measurement of circulating markers in patients with neuroendocrine tumours of the pancreas and gut. Endocr Relat Cancer 2003; 10: 459-462.

35. Feldman JM, O'Dorisio TM: Role of neuropeptides and serotonin in the diagnosis of carcinoid tumors. Am J Med 1986; 81: 41-48.

36. Eriksson B, Oberg K: Peptide hormones as tumor markers in neuroendocrine gastrointestinal tumors. Acta Oncol 1991; 30: 477483.

37. Hamilton SR AL: Tumors of the digestive system. Pathology and Genetics. WHO Classification of Tumours. Lyon, ARC Press, 2000.

38. Rindi G, Kloppel G, Alhman H , et al: TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006; 449: 395-401.

39. Hemminki K, Li X: Incidence trends and risk factors of carcinoid tumors: a nationwide epidemiologic study from Sweden. Cancer 2001; 92: 2204-2210.

40. Hemminki K, Li X: Familial carcinoid tumors and subsequent cancers: a nationwide epidemiologic study from Sweden. Int J Cancer 2001; 94: 444-448.

41. Akerstrom G, Makridis C, Johansson H: Abdominal surgery in patients with midgut carcinoid tumors. Acta Oncol 1991; 30: 547-553.

42. Rothmund M, Kisker O: Surgical treatment of carcinoid tumors of the small bowel, appendix, colon and rectum. Digestion 1994; 55(suppl 3):86-91.

43. Ahlman H, Wangberg B, Jansson S , et al: Interventional treatment of gastrointestinal neuroendocrine tumours. Digestion 2000; 62(suppl 1):59-68.

44. Makridis C, Oberg K, Juhlin C , et al: Surgical treatment of mid-gut carcinoid tumors. World J Surg 1990; 14: 377-384.

45. Norton JA: Surgical management of carcinoid tumors: role of debulking and surgery for patients with advanced disease. Digestion 1994; 55(suppl 3):98-103.

46. Goede AC, Winslet MC: Surgery for carcinoid tumours of the lower gastrointestinal tract. Colorectal Dis 2003; 5: 123-128.

47. Frilling A, Rogiers X, Malago M, Liedke OM,Kaun M, Broelsch CE: Treatment of liver metastases in patients with neuroendocrine tumors. Langenbecks Arch Surg 1998; 383: 6270.

48. Lehnert T, Knaebel HP: Diagnosis and therapy of liver metastases of neuroendocrine tumors in German). hirurg 1997; 68: 122131.

49. Chen H, Hardacre JM, Uzar A, Cameron JL, Choti MA: Isolated liver metastases from neuroendocrine tumors: does resection prolong survival? J Am Coll Surg 1998; 187: 8893.

50. Que FG, Nagorney DM, Batts KP, Linz LJ, Kvols LK: Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg 1995; 169: 36^3.

51. Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que FG: Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 2003; 197: 29-37.

52. Chamberlain RS, Canes D, Brown KT , et al: Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg 2000; 190: 432-445.

53. Norton JA, Warren RS, Kelly MG, Zuraek MB, Jensen RT: Aggressive surgery for metastatic liver neuroendocrine tumors. Surgery 2003; 134: 1057-1065.

54. Soreide O, Berstad T, Bakka A , et al: Surgical treatment as a principle in patients with advanced abdominal carcinoid tumors. Surgery 1992; 111: 48-54.

55. Moertel CG, Sauer WG, Dockerty MB, Baggenstoss AH: Life history ofthe carcinoid tumor ofthe small intestine. Cancer 1961; 14: 901-912.

56. Dousset B, Saint-Marc O, Pitre J, Soubrane O, Houssin D, Chapuis Y: Metastatic endocrine tumors: medical treatment, surgical resection, or liver transplantation. World J Surg 1996; 20: 908-915.

57. Chung MH, Pisegna J, Spirt M , et al: Hepatic cytoreduction followed by a novel long-acting somatostatin analog: a paradigm for intractable neuroendocrine tumors metastatic to the liver. Surgery 2001; 130: 954-962.

58. Wangberg B, Westberg G, Tylen U , et al: Survival of patients with disseminated midgut carcinoid tumors after aggressive tumor reduction.World JSurg 1996;20:892-899.

59. McEntee GP, Nagorney DM, Kvols LK, Moertel CG, Grant CS: Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery 1990; 108: 1091-1096.

60. Eriksson B, Oberg K: Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlook. Ann Oncol 1999; 10(suppl 2):S31-S38.

61. Eriksson B, Renstrup J, Imam H, Oberg K: High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects. Ann Oncol 1997; 8: 1041-1044.

62. Wymenga AN, Eriksson B, Salmela PI , et al: Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. J Clin Oncol 1999; 17: 1111.

63. Ducreux M, Ruszniewski P, Chayvialle JA , et ак The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. Am J Gastroenterol 2000; 95: 3276-3281.

64. Di Bartolomeo M, Bajetta E, Buzzoni R , et al: Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medi cal Oncology Group. Cancer 1996; 77: 402408.

65. Arnold R, Trautmann ME, Creutzfeldt W , et al: Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut 1996; 38: 430-438.

66. Aparicio T, Ducreux M, Baudin E , et al: Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. Eur J Cancer 2001; 37: 10141019.

67. O'Toole D, Ducreux M, Bommelaer G , et al:Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer 2000; 88: 770-776.

68. Ruszniewski P, Ducreux M, Chayvialle JA , et al: Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients. Gut 1996; 39: 279-283.

69. Tomassetti P, Migliori M, Gullo L: Slow-release lanreotide treatment in endocrine gastrointestinal tumors. Am J Gastroenterol 1998; 93: 1468-1471.

70. Tomassetti P, Migliori M, Corinaldesi R, Gullo L: Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR. Aliment Pharmacol Ther 2000; 14: 557-560.

71. Faiss S, Pape UF, Bohmig M , et al: Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors The International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 2003; 21: 2689-2696.

72. Rubin J, Ajani J, Schirmer W , et al: Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol 1999; 17: 600-606.

73. Ricci S, Antonuzzo A, Galli L , et al: Octreotide аcetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide. Ann Oncol 2000; 11: 1127-1130.

74. Leong WL, Pasieka JL: Regression of metastatic carcinoid tumors with octreotide therapy: two case reports and a review of the literature. J Surg Oncol 2002; 79: 180187.

75. Saltz L, Trochanowski B, Buckley M , et al:Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. Cancer 1993; 72: 244-248.

76. Plockinger U, Dienemann D, Quabbe HJ: Gastrointestinal side-effects of octreotide during long-term treatment of acromegaly. J Clin Endocrinol Metab 1990; 71: 16581662.